Lead Plaintiff Deadline is April 26, 2019

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that  a  federal securities class action  lawsuit has been  filed in  the United States  District Court for  the Southern  District of  New York  on behalf  of all  investors who  purchased  or  otherwise  acquired  AVEO  Pharmaceuticals,  Inc.  (NASDAQ: AVEO) securities  between August 4,  2016 and January  31, 2019  (the “Class Period”), inclusive.  

Investors who purchased shares of AVEO Pharmaceuticals, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website www.whafh.com.

If you have incurred losses in the shares of AVEO  Pharmaceuticals,  Inc.,   you may, no later than April 26, 2019, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in   AVEO  Pharmaceuticals,  Inc.    

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

The filed complaint alleges  that  throughout  the class period defendants made  false and/or misleading statements and/or  failed to disclose  that:

• the  TIVO-3 trial was  inadequately  designed to  address  the overall  survival  concerns regarding AVEO’s  lead  candidate  drug,  tivozanib,  from  the  TIVO-1  trial presented back in the June 2013;
   
• tivozanib had insufficient survival  data to obtain U.S.  Food and  Drug Administration (“FDA”)  approval following  its initial rejection by  the FDA in  2013;
   
• this  lack of sufficient  survival data would put tivozanib at greater risk of delayed FDA approval; and
   
• as a result, AVEO’s public statements were  materially false and misleading at  all relevant times.

Wolf Haldenstein Adler Freeman & Herz LLP  has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.